Keryx Biopharmaceuticals Announces Appointment Of Douglass H. Laidlaw, Ph.D., As Director, Medical Affairs

NEW YORK, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced the appointment of Douglass H. Laidlaw, Ph.D. to the newly created position of Director, Medical Affairs, with oversight of the creation and activities of the Company's Medical Science Liaisons (MSL) team.

Dr. Laidlaw joins the Company from Genzyme/Sanofi (NYSE:SNY), where since 2007 he has worked in the Medical Affairs division, most recently serving as National Director, Medical Science Liaisons (MSL) of the Renal Division. During his tenure at Genzyme/Sanofi, Dr. Laidlaw was well recognized for the strategic development and implementation of many key projects contributing to the success of the Renal business unit, notably initiatives surrounding prelaunch activities and generating scientific support aimed at increasing awareness of acute and chronic kidney disease and its sequelae. Dr. Laidlaw has extensive experience recruiting, managing and leading field based teams of MSLs. 

Ron Bentsur, the Company's Chief Executive Officer, commented, "We are excited to be welcoming Dr. Laidlaw to the Company. Dr. Laidlaw brings a proven track record of success in the development and leadership of a dedicated renal MSL team, strategic planning capabilities and a vast network of relationships within the nephrology community. I am confident that he will be an extraordinary asset as we build out our marketing organization."

Dr. Laidlaw earned his Ph.D. in Physiological Sciences from the University of Arizona. His academic research career included positions in Biomedical Engineering at The Cleveland Clinic Foundation and in the Department of Integrative Physiology at the University of Colorado, Boulder.

Previous to his employment with Genzyme, from 2006-2007, he held the position of Associate Director Medical Affairs, Medical and Education Liaisons with Neurocrine Biosciences and was a core member of the team responsible for creating their Medical Affairs infrastructure. Prior to that time, from 2003-2006, he was a Senior Medical Science Liaison at Serono.  He began his career in the biopharmaceutical industry as a Regional Medical Liaison with Organon.

If you liked this article you might like

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

5 Breakout Stocks Under $10 Set to Soar

Today's Perilous Reversal Stock: Keryx Biopharmaceuticals (KERX)